Cai Wen-Ke, Zhang Jia-Bin, Wang Niu-Min, Wang Ying-Lin, Zhao Can-Hu, Lu Jun, He Gong-Hao
Department of Cardio-Thoracic Surgery, Kunming General Hospital of Chengdu Military Region, Kunming 650032, China ; Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming 650032, China.
Hepatobiliary Surgery Center, 302 Hospital, Beijing 100039, China.
ScientificWorldJournal. 2015;2015:545292. doi: 10.1155/2015/545292. Epub 2015 Apr 2.
Histamine H2 receptor (HRH2) was previously suggested to affect the proliferation of breast cancer cells and disease-free survival of breast cancer patients. Furthermore, a common polymorphism, rs2067474, was identified in an enhancer element of the HRH2 gene promoter and was reported to be associated with various diseases including cancer. However, the relationship between this polymorphism and breast cancer risk and malignant degree remains unclear. The aim of this study was to clarify the clinical association of rs2067474 polymorphism with breast cancer. A total of 201 unrelated Chinese Han breast cancer patients and 238 ethnicity-matched health controls were recruited and rs2067474 polymorphism was genotyped. Logistic regression analyses were performed to calculate the odds ratios (ORs) as a measure of association of genotype with breast cancer according to 3 genetic models (dominant, recessive, and additive). Although the percentage of hormone receptor negative cases tended to be higher in AA genotypes, we did not find any significant associations of rs2067474 polymorphism with breast cancer risk or with related clinicopathological parameters in the present study, which indicates that rs2067474 polymorphism of HRH2 gene might not be a risk factor in the development of breast cancer in Chinese Han population.
组胺H2受体(HRH2)此前被认为会影响乳腺癌细胞的增殖以及乳腺癌患者的无病生存期。此外,在HRH2基因启动子的一个增强子元件中发现了一种常见的多态性rs2067474,据报道它与包括癌症在内的多种疾病有关。然而,这种多态性与乳腺癌风险及恶性程度之间的关系仍不清楚。本研究的目的是阐明rs2067474多态性与乳腺癌的临床关联。共招募了201名无亲缘关系的中国汉族乳腺癌患者和238名种族匹配的健康对照,并对rs2067474多态性进行基因分型。根据三种遗传模型(显性、隐性和加性)进行逻辑回归分析,以计算优势比(OR)作为基因型与乳腺癌关联的衡量指标。尽管AA基因型中激素受体阴性病例的比例倾向于更高,但在本研究中我们未发现rs2067474多态性与乳腺癌风险或相关临床病理参数之间存在任何显著关联,这表明HRH2基因的rs2067474多态性可能不是中国汉族人群乳腺癌发生的危险因素。